2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Study Population, Human, Adult, Animal Model
PAPER

1442 Single-cell profiling reveals a premalignant progenitor state in cebpaNterm-mutated zebrafish

Zhangjie Chen, MD, Alexandra Lubin, PhD2, Tanvi Tambaku, MRes3, Katie-Jo Thorpe, BSc4, Catherine Zhu5, Elspeth Payne, MD PhD FRCPath6
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China, University College London Cancer Institute, London, United Kingdom
2 University College London Cancer Institute, London, United Kingdom
3 University College London Cancer Institute, London, United Kingdom
4 University College London Cancer Institute, London, United Kingdom
5 University College London Cancer Institute, London, United Kingdom
6 University College London Cancer Institute, London, United Kingdom

Background: CEBPA encodes a transcription factor essential for granulocyte differentiation. It is mutated in 10-15% of acute myeloid leukemia (AML), with approximately 10% of cases being inherited. A truncating germline N-terminal (CEBPANterm) mutation typically serves as the founder event, while acquisition of a C-terminal (CEBPACterm) BZIP mutation on the alternate allele is associated with progression to AML. However, the cellular and molecular changes that precede leukemic transformation remain poorly understood.

 

Aim: Using zebrafish models developed in our lab, we aimed to identify premalignant hematopoietic cell populations associated with germline cebpaNterm mutation and nominate candidate genes contributing to leukemogenesis.

 

Methods: TALEN mRNA targeting cebpacterm region was microinjected into one-cell stage heterozygous cebpaNterm reporter embryos carrying lysC:mCherry and cd41:GFP genes. Whole-fish flow cytometry was performed at 2 and 4 weeks, and cebpacterm editing was confirmed and quantified by MiSeq. scRNA-seq (Parse Biosciences Evercode WT) was performed on heterozygous cebpaNterm and wild-type (WT) zebrafish at 4 days, 2 weeks, 6 months and 16 months. Single-cell suspensions were prepared from whole larvae at 4d and 2w, and from adult kidney marrow at 6m and 16m, granulocytes and progenitor clusters were subsetted for high-resolution analysis.

 

Results: MiSeq confirmed cebpacterm editing in all analyzed fish, with pooled edited-read frequencies of 44% and 54% at 2 and 4 weeks, respectively. Compared with uninjected control, cebpaCterm-edited cebpaNterm zebrafish showed a significant reduction in lysC:mCherry myeloid cells at 2 weeks (1.29±0.74% vs. 2.88±0.87%, P<0.001), with a similar trend at 4 weeks (1.52±0.98% vs. 2.24±1.55%, P=0.055). In contrast, cd41:GFP progenitor proportions were not significantly altered. By 8 weeks, cebpaNterm fish with cebpaCterm editing developed leukemic-associated features, including emergence of an aberrant cell population and tumor-like lesions, while zebrafish carrying either mutation alone survived into adulthood without overt leukemia. These findings suggested that cebpaNterm may establish a molecularly dysregulated progenitor state that is phenotypically unmasked by acquisition of a cooperating cebpaCterm mutation.

 

To define the premalignant state associated with the cebpaNterm founder mutation, age-resolved scRNA-seq analysis was performed. Mutants revealed progressive expansion of granulocytes cluster, accompanied by relative depletion of GMP and HSPC subpopulations in cebpaNterm mutants. In adult mutants, granulocytes exhibited progressively downregulated ribosomal and translational programs while upregulating inflammatory and cell death pathways. A subset of haematopoietic stem and progenitor cells with expression of myeloid markers (HSPC1), showed increased cell-cycle activity and impaired differentiation-associated programs. Trajectory analysis positioned HSPC1 upstream of GMP and granulocytes. Ligand-receptor analysis further predicted reduced NECTIN3-TIGIT interactions between HSPC1 and granulocytes or T cells.

 

To prioritize candidate contributor of this abnormal progenitor state, genes upregulated in 6-month mutant HSPC1 were screened using GSE270550, an independent N-terminal CEBPA/p30 model dataset. Gene timeless was significantly upregulated in HPC-7 progenitor-like cells and showed a concordant upward trend in primary mouse HSPCs. Predicted timeless knockdown across HSPC/GMP populations revealed mutant-specific vulnerability. In 6-month cebpaNterm cells, affected genes were enriched for chromosome segregation, mitotic cell cycle, and regulation of chromosome organization, consistent with the hyperproliferative phenotype, while WT cells showed only perturbation of membrane organization.

 

Conclusion: Germline cebpaNterm mutation is associated with an age-dependent emergence of granulocyte-primed, differentiation-impaired progenitor states before overt leukemia. Acquisition of cebpaCterm mutation may unmasks an early myeloid differentiation defect and promote leukemogenesis. Single-cell analysis and simulation knockdown prioritize timeless as a potential candidate associated with dysregulated progenitors, requiring functional validation.

Zhangjie Chen, MD: No relevant conflicts of interest to declare.